Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)

Am J Cardiol. 2002 Sep 1;90(5):526-9. doi: 10.1016/s0002-9149(02)02528-6.

Authors

Annapoorna S Kini¹, Merwin Richard, Javed Suleman, Nohelia Perez, Paul Lee, Edward A Fisher, Mazullah Kamran, Jonathan D Marmur, Samin K Sharma

Affiliation

¹ Cardiac Catheterization Laboratory of the Zena & Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York 10029, USA.

PMID: 12208416
DOI: 10.1016/s0002-9149(02)02528-6

No abstract available

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Abciximab
Aged
Angioplasty, Balloon, Coronary* / economics
Antibodies, Monoclonal / economics
Antibodies, Monoclonal / therapeutic use*
Cardiac Catheterization / economics
Cardiomyopathies / pathology*
Combined Modality Therapy
Creatine Kinase / blood
Creatine Kinase, MB Form
Eptifibatide
Female
Humans
Immunoglobulin Fab Fragments / economics
Immunoglobulin Fab Fragments / therapeutic use*
Incidence
Isoenzymes / blood
Male
Middle Aged
Myocardial Infarction / epidemiology
Myocardial Infarction / therapy
Necrosis
Peptides / economics
Peptides / therapeutic use*
Pilot Projects
Platelet Aggregation Inhibitors / economics
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / economics
Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use
Predictive Value of Tests
Stroke Volume / physiology
Tirofiban
Treatment Outcome
Troponin I / blood
Tyrosine / analogs & derivatives*
Tyrosine / economics
Tyrosine / therapeutic use*

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Isoenzymes
Peptides
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Troponin I
Tyrosine
Creatine Kinase
Creatine Kinase, MB Form
Tirofiban
Eptifibatide
Abciximab